Harbour Capital Advisors, LLC Dexcom Inc Transaction History

Harbour Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 16, 2024	SELL	$114.22 - $140.1 $30,268 - $37,126	-265 Reduced 2.27%	11,405 $1.58 Million
Q4 2023 Jan 05, 2024	SELL	$75.49 - $124.16 $16,985 - $27,936	-225 Reduced 1.89%	11,670 $1.45 Million
Q3 2023 Oct 05, 2023	BUY	$86.06 - $137.93 $108,005 - $173,102	1,255 Added 11.8%	11,895 $1.11 Million
Q2 2023 Jul 10, 2023	SELL	$112.47 - $130.98 $12,596 - $14,669	-112 Reduced 1.04%	10,640 $1.37 Million
Q1 2023 Apr 19, 2023	BUY	$104.0 - $122.92 $391,040 - $462,179	3,760 Added 53.78%	10,752 $1.25 Million
Q4 2022 Jan 13, 2023	BUY	$84.98 - $122.67 $276,779 - $399,536	3,257 Added 87.2%	6,992 $0
Q3 2022 Oct 19, 2022	BUY	$76.35 - $94.18 $285,167 - $351,762	3,735 New	3,735 $374,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Harbour Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Harbour Capital Advisors, LLC with notifications on news.